Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial by Freeman, SD, Thomas, A, Thomas, I, Hills, RK, Vyas, P, Gilkes, AF, Metzner, M, Jakobsen, NA, Kennedy, A, Moore, AR, Marquez-Almuina, N, Burns, S, King, S, Andrew, G, Gallagher, KME, Sellar, RS, Cahalin, PA, Weber, D, Dennis, M, Mehta, P, Knapper, S, Russell, NH